Literature DB >> 26475367

Hypereosinophilic Syndrome.

Casey Curtis1, Princess Ogbogu2.   

Abstract

Hypereosinophilic syndrome consists of a group of disorders characterized by abnormal accumulation of eosinophils in the blood or peripheral tissues, independent of known secondary causes of eosinophilia such as parasitic infection. Clinical manifestations of the condition are highly variable, ranging from asymptomatic eosinophilia to severe tissue damage and end-organ failure. This entity has been recognized for decades, with early studies identifying distinct groups of patients with differing symptoms, exam findings, laboratory abnormalities, and prognosis. In the past, these patients were treated with non-targeted immunosuppressive agents, often with limited efficacy. More recently, advances in the knowledge of eosinophil biology and molecular diagnostics have allowed for more specific delineation of the many disease subgroups that characterize hypereosinophilic syndrome. Identification of these groups has led to a personalized management approach to the condition, with improved diagnostic techniques as well as stratification of patients into more effective treatment groups. This review will discuss the evolution of the definition of hypereosinophilic syndrome, outline current disease classifications, provide a guide for evaluation and monitoring, and discuss current and future therapeutic modalities.

Entities:  

Keywords:  CEL; Chronic eosinophilic leukemia; Eosinophilia; FIP1L1-PDGFRA; HES; Hypereosinophilic syndrome; L-HES; M-HES

Mesh:

Year:  2016        PMID: 26475367     DOI: 10.1007/s12016-015-8506-7

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   10.817


  47 in total

1.  Interferon-alpha for the hypereosinophilic syndrome.

Authors:  R M Zielinski; W D Lawrence
Journal:  Ann Intern Med       Date:  1990-11-01       Impact factor: 25.391

Review 2.  Hypereosinophilic syndrome: current approach to diagnosis and treatment.

Authors:  Amy Klion
Journal:  Annu Rev Med       Date:  2009       Impact factor: 13.739

Review 3.  World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.

Authors:  Jason Gotlib
Journal:  Am J Hematol       Date:  2011-08       Impact factor: 10.047

4.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors:  Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

5.  FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.

Authors:  A Pardanani; R P Ketterling; C-Y Li; M M Patnaik; A P Wolanskyj; M A Elliott; J K Camoriano; J H Butterfield; G W Dewald; A Tefferi
Journal:  Leuk Res       Date:  2006-01-06       Impact factor: 3.156

Review 6.  Refining the definition of hypereosinophilic syndrome.

Authors:  Hans-Uwe Simon; Marc E Rothenberg; Bruce S Bochner; Peter F Weller; Andrew J Wardlaw; Michael E Wechsler; Lanny J Rosenwasser; Florence Roufosse; Gerald J Gleich; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2010-07       Impact factor: 10.793

7.  Treatment of patients with the hypereosinophilic syndrome with mepolizumab.

Authors:  Marc E Rothenberg; Amy D Klion; Florence E Roufosse; Jean Emmanuel Kahn; Peter F Weller; Hans-Uwe Simon; Lawrence B Schwartz; Lanny J Rosenwasser; Johannes Ring; Elaine F Griffin; Ann E Haig; Paul I H Frewer; Jacqueline M Parkin; Gerald J Gleich
Journal:  N Engl J Med       Date:  2008-03-16       Impact factor: 91.245

Review 8.  Cardiovascular manifestations of hypereosinophilic syndromes.

Authors:  Princess U Ogbogu; Douglas R Rosing; McDonald K Horne
Journal:  Immunol Allergy Clin North Am       Date:  2007-08       Impact factor: 3.479

Review 9.  Gastrointestinal eosinophilia.

Authors:  Li Zuo; Marc E Rothenberg
Journal:  Immunol Allergy Clin North Am       Date:  2007-08       Impact factor: 3.479

10.  Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.

Authors:  Irina Sadovnik; Els Lierman; Barbara Peter; Harald Herrmann; Verena Suppan; Gabriele Stefanzl; Oskar Haas; Thomas Lion; Winfried Pickl; Jan Cools; Peter Vandenberghe; Peter Valent
Journal:  Exp Hematol       Date:  2014-01-06       Impact factor: 3.084

View more
  35 in total

1.  FIP1L1-PDGFRA fusion-negative hypereosinophilic syndrome with uncommon cardiac involvement responding to imatinib treatment: A case report.

Authors:  Amanda Santos Dal Berto; Ricardo Hohmann Camiña; Eduardo Silva Machado; Antuani Rafael Baptistella
Journal:  Mol Clin Oncol       Date:  2018-05-21

2.  Could hypereosinophilia at diagnosis estimate the current activity or predict relapse in systemic immunosuppressive drug-naïve patients with eosinophilic granulomatosis with polyangiitis?

Authors:  Juyoung Yoo; Sung Soo Ahn; Seung Min Jung; Jason Jungsik Song; Yong-Beom Park; Sang-Won Lee
Journal:  Rheumatol Int       Date:  2019-07-13       Impact factor: 2.631

3.  Gene therapy in a murine model of chronic eosinophilic leukemia-not otherwise specified (CEL-NOS).

Authors:  Odelya E Pagovich; Katie M Stiles; Anna E Camilleri; Anthony R Russo; Saparja Nag; Ronald G Crystal
Journal:  Leukemia       Date:  2021-09-20       Impact factor: 11.528

4.  Unravelling the NERDS syndrome.

Authors:  Achintya Dinesh Singh; Tejas Menon Suri; Rakesh Kumar Jagdish; Uma Kumar
Journal:  BMJ Case Rep       Date:  2018-05-12

Review 5.  DEK-NUP214-Fusion Identified by RNA-Sequencing of an Acute Myeloid Leukemia with t(9;12)(q34;q15).

Authors:  Ioannis Panagopoulos; Ludmila Gorunova; Synne Torkildsen; Geir E Tjønnfjord; Francesca Micci; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2017 Nov-Dec       Impact factor: 4.069

6.  Investigating Febrile Polyserositis: An Unusual Case of Idiopathic Hypereosinophilic Syndrome.

Authors:  Inês Rueff Rato; Joana Rigor; Paula Ferreira; Joana Laranjinha; Gualter Santos-Silva; Daniela Martins-Mendes
Journal:  Eur J Case Rep Intern Med       Date:  2021-04-02

Review 7.  Eosinophils as Major Player in Type 2 Inflammation: Autoimmunity and Beyond.

Authors:  Marco Folci; Giacomo Ramponi; Ivan Arcari; Aurora Zumbo; Enrico Brunetta
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 8.  What does elevated TARC/CCL17 expression tell us about eosinophilic disorders?

Authors:  Julien Catherine; Florence Roufosse
Journal:  Semin Immunopathol       Date:  2021-05-19       Impact factor: 9.623

Review 9.  Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity.

Authors:  Peter Valent; Lina Degenfeld-Schonburg; Irina Sadovnik; Hans-Peter Horny; Michel Arock; Hans-Uwe Simon; Andreas Reiter; Bruce S Bochner
Journal:  Semin Immunopathol       Date:  2021-05-30       Impact factor: 9.623

10.  Crusted Scabies Induced Hypereosinophilic Syndrome.

Authors:  Asis Shrestha; Edward Bischof
Journal:  Cureus       Date:  2021-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.